STOCK TITAN
  1. Home
  2. Sec-filings
  3. TMCI
  4. [Form 4] TREACE MEDICAL CONCEPTS, INC. Insider Trading Activity

Treace Medical (TMCI) awards 30,000 RSUs to company director

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

HAMILTON LAWRENCE W reported acquisition or exercise transactions in this Form 4 filing.

Treace Medical Concepts director Lawrence W. Hamilton reported a grant of 30,000 restricted stock units (RSUs) of Common Stock. The award was recorded at a price of $0.00 per share, reflecting a stock-based compensation grant rather than an open-market purchase.

The RSUs will be 100% vested on the earlier of May 19, 2027 or the 2027 annual meeting of stockholders, as long as Hamilton continues serving the company through that date. He has elected to defer receipt of the underlying shares until the earlier of a change in control or his separation of service. After this grant, his direct holdings total 74,056 shares, including 30,000 RSUs.

Positive

  • None.

Negative

  • None.
Insider HAMILTON LAWRENCE W
Role null
Type Security Shares Price Value
Grant/Award Common Stock 30,000 $0.00 --
Holdings After Transaction: Common Stock — 74,056 shares (Direct, null)
Footnotes (1)
  1. Represents restricted stock units (RSUs) for which the Reporting Person is entitled to receive one (1) share of Issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on the earlier of (a) May 19, 2027 or (b) the date of the 2027 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through the vesting date. The Reporting Person voluntarily elected to defer receipt of the shares of the Issuer's Common Stock issuable upon settlement of the RSUs until the earlier of a change in control or the Reporting Person's separation of service to the Issuer. Includes 30,000 restricted stock units.
RSU grant size 30,000 RSUs Restricted stock units granted on May 19, 2026
Grant price per share $0.00 per share Reported value for RSU award
Total holdings after grant 74,056 shares Direct holdings following the RSU grant
Vesting date trigger Earlier of May 19, 2027 or 2027 annual meeting 100% RSU vesting condition
Transaction direction count 1 acquisition Form 4 transaction summary for this filing
restricted stock units (RSUs) financial
"Represents restricted stock units (RSUs) for which the Reporting Person is entitled to receive one (1) share"
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
change in control financial
"defer receipt of the shares ... until the earlier of a change in control or the Reporting Person's separation"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
separation of service financial
"until the earlier of a change in control or the Reporting Person's separation of service to the Issuer"
annual meeting of stockholders financial
"the earlier of (a) May 19, 2027 or (b) the date of the 2027 annual meeting of stockholders"
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
HAMILTON LAWRENCE W
(Last)(First)(Middle)
C/O TREACE MEDICAL CONCEPTS, INC.
100 PALMETTO PARK PLACE
(Street)
PONTE VEDRA FLORIDA 32081
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
TREACE MEDICAL CONCEPTS, INC. [ TMCI ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/19/2026A30,000(1)A$074,056(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents restricted stock units (RSUs) for which the Reporting Person is entitled to receive one (1) share of Issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on the earlier of (a) May 19, 2027 or (b) the date of the 2027 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through the vesting date. The Reporting Person voluntarily elected to defer receipt of the shares of the Issuer's Common Stock issuable upon settlement of the RSUs until the earlier of a change in control or the Reporting Person's separation of service to the Issuer.
2. Includes 30,000 restricted stock units.
/s/ Lisa Taylor as Attorney-in-fact for Lawrence Hamilton05/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did TMCI director Lawrence W. Hamilton report?

Lawrence W. Hamilton reported receiving a grant of 30,000 restricted stock units (RSUs) of Treace Medical Concepts common stock. This is a stock-based compensation award, not an open-market trade, and increases his total reported direct holdings in the company.

How many Treace Medical Concepts (TMCI) RSUs were granted to Hamilton?

Hamilton was granted 30,000 restricted stock units (RSUs) tied to Treace Medical Concepts common stock. Each RSU represents the right to receive one share upon settlement, subject to vesting and his continued service with the company through the vesting date.

What is the vesting schedule for Hamilton’s 30,000 TMCI RSUs?

The 30,000 RSUs will be 100% vested on the earlier of May 19, 2027 or the date of Treace Medical Concepts’ 2027 annual meeting of stockholders. Vesting is conditioned on Hamilton’s continued service to the company through that vesting date.

Did Lawrence W. Hamilton pay cash for the 30,000 TMCI RSUs?

No cash was paid for the award; the RSUs were granted at a reported price of $0.00 per share. This indicates a compensation grant rather than a market purchase and reflects equity-based pay from Treace Medical Concepts.

When will Hamilton receive the TMCI shares underlying his RSUs?

Hamilton elected to defer receiving the shares until the earlier of a change in control of Treace Medical Concepts or his separation of service. This means share delivery is postponed beyond vesting until one of those events occurs.

What are Hamilton’s total TMCI holdings after this RSU grant?

Following the grant, Hamilton’s direct holdings total 74,056 shares of Treace Medical Concepts common stock. This figure includes the 30,000 restricted stock units referenced in the filing, as noted in the accompanying footnote disclosure.